Fujisawa Pharmaceutical Company, Ltd.

Keizo Yoshida

Masanobu Kohsaka

Hirokazu Tanaka

Hiroshi Imanaka

Yoshiko Ueda

Hiroyuki Takamatsu

Kiyotaka Katsuta

Hajime Nakanishi

Itsuo Uchida

Kazuyoshi Umehara

Hatsuo Aoki

Masanori Okamoto

Morita Iwami

Eiko Iguchi

Hiroyuki Kikuchi

Motoaki Nishikawa

Takashi Fujii

Compounds for treating or preventing cerebrovascular diseases are disclosed. These compounds are 5-HT antagonists. More specifically, these compounds, when combined with pharmaceutically acceptable carriers or excipients and administered to animals including humans, are useful in treating or preventing cerebrovascular dementia.

Medicament for treating or preventing cerebrovascular dementia

Medicament for treating or preventing cerebrovascular infarction

This invention relates to a biologically active WS-7739-A substance and a biologically active WS-7739-B substance which have pharmacological activities and are useful for the treatment of asthma, thrombosis and the alike.

WS 7739 substances, their preparation and pharmaceutical composition

N-acylpeptides are disclosed of the formula: ##STR1## wherein R.sup.1 is alkanoyloxy or alkenoyloxy; R.sup.2 is alkyl or alkenyl; R.sup.3 and R.sup.4 are each lower alkyl, hydroxy(lower)alkyl, ar(lower)alkyl, esterified carboxy(lower)alkyl, carboxy(lower)alkyl, protected amino(lower)alkyl or amino(lower)alkyl; R.sup.5 is hydrogen, hydroxy(lower)alkyl, protected amino(lower)alkyl, amino(lower)alkyl, carboxy(lower)alkyl or esterified carboxy(lower)alkyl; R.sup.6 is carboxy, esterified carboxy or sulfo(lower)alkyl; A.sup.1, A.sup.2 and A.sup.3 are each bond or lower alkylene; and m and n are each an integer of 0 or 1; or its pharmaceutically acceptable salt. These compounds have anti-complementary activity and fibrinolytic activity, and are useful as therapeutic agents for immune-complex diseases or autoimmune diseases such as nephritis, rheumatic diseases, systemic lupus erythematosus, etc. and thrombosis such as cerebral apoplexy, coronary insufficiency, pulmonary embolism, etc.

N-acyl peptide, processes for their preparation and pharmaceutical

This invention relates to new N-acylpeptide compounds of immunological activity, said compounds being of the formula: ##EQU1## wherein R.sup.1 and R.sup.2 are each alkyl or alkenyl;

N-Acylpeptide compound, processes for the preparation thereof and the

Alkyl, alkenyl, and aryl substituted triazene compounds, their salts and

Hyaluronidase obtained from Streptomyces koganeiensis has the following characteristics:

Novel hyaluronidase BMP-8231 and production thereof

Growing community of inventors

Suita, Japan

Keizo Yoshida